Mersana Therapeutics, Inc. shared unaudited and preliminary financial information, stating that it had $286.6 million in cash, cash equivalents, and marketable securities as of June 30, 2023. The company also announced the discontinuation of its clinical development of UpRi and a reduction of approximately 50% of its employee base as part of a restructuring plan.